Refuge Biotechnologies Inc.
8 articles about Refuge Biotechnologies Inc.
-
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
10/20/2022
Kite, a Gilead Company (Nasdaq: GILD) and Refuge Biotechnologies, Inc. (“Refuge”), today announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for cancer immunotherapy, for exclusive rights to utilize Refuge’s proprietary gene expression platform to develop potential treatments for blood cancers.
-
MD Anderson and Refuge Biotechnologies Collaborate to Advance Next-Generation Cell Therapies for Treatment of Solid Tumors
5/17/2021
Collaboration supports co-development of RB-340, a HER-2 targeted CAR T- cell therapy with context-dependent and inducible down-regulation of PD-1, through Phase 2 MD Anderson to apply Refuge’s synthetic biology platform to TIL programs
-
Refuge Biotechnologies Promotes Francesco M. Marincola, M.D., to President
3/9/2020
Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, today announced the promotion of Francesco M. Marincola, M.D., to president.
-
Refuge Biotechnologies to Present at Biotech Showcase™ 2020
1/6/2020
Refuge Biotechnologies, Inc. announced that Bing Wang, Ph.D., Co-Founder and Chief Executive Officer, will present a corporate update on Tuesday, January 14, 2020 at Biotech Showcase™ being held in San Francisco, from January 13-15, 2020.
-
Refuge Biotechnologies to Present During Multi-Targeted Therapeutic Platforms Program at The Annual Meeting of The Society for Immunotherapy of Cancer
10/30/2019
Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, today announced that Francesco M. Marincola, M.D., chief scientific officer of Refuge, will present during the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting & Pre-Conference Programs (SITC 2019).
-
Refuge Biotechnologies to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
10/1/2019
Refuge Biotechnologies, Inc. announced that Bing Wang, Ph.D., Co-Founder and Chief Executive Officer of Refuge, is scheduled to present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019 at 8:55 AM ET.
-
Refuge Biotechnologies Appoints Scott Smith to Board of Directors
10/15/2018
Former President and COO of Celgene to Help Guide Pipeline and Corporate Development Activities.
-
Chinese investment firms 3SBio and Sequoia China joined a team of other investors to bankroll California-based Refuge Biotechnologies, Inc.’s $25 million funding round to support its gene therapy treatments using CRISPR technology.